
Reprogramming brain aging to prevent dementia
NeuroAge Therapeutics has developed a prognostic test to determine people’s biological brain age and their future risk of neurodegenerative disorders more than 30 years ahead of time. The NeuroAge Test combines brain MRI with cognitive testing, blood RNA seq, and genetics. They use data from this test to provide personalized lifestyle recommendations to slow down or reverse brain aging. The invaluable dataset created from the NeuroAge Test also informs their Alzheimer’s therapeutics program.
Our Speaker

Dr. Christin Glorioso
Dr. Christin Glorioso is a neuroscientist, physician, and serial entrepreneur. She is co-founder and CEO of NeuroAge Therapeutics and Founder and Executive Director of the non-profit, Longevity Global. Previously she was Head of AI of the Stanford Spinout, TeachAids, and Chief Strategist of UCSF’s Bakar Aging Research Institute. She has published more than 30 peer reviewed publications and been awarded funding by ADDF, AFAR, the Glenn Foundation for Medical Research, and the National Institute on Aging. Dr. Glorioso holds an MD and PhD in Neuroscience from the University of Pittsburgh and Carnegie Mellon University’s Medical Scientist Training Program and completed her postdoctoral training at MIT.